Sector trading at '24e-'25e P/Es of 8.5x and 9.1x, with abating NIM, and at '23e P/BV 1.2x with normalised ROE of ~14%, still attractive. Adj. EPS up for '24e, down for '25e; we prefer SVEG & MING.
Q4e: PTP NOK 355m, short-term headwinds from increased costs. Lending growth refocus towards growth as part of a new bank. Shareholder value created in the merger with SRBNK - HOLD.
Sp1 banks are allowed to establish "new" Sp1 Markets. Gains will be moved from Q1'24e to Q4'23e and add to dividend capacity. Prefer MING and SVEG in Norway on more attractive valuation.
The merger news with SRBNK overshadowed a weaker Q3. We trim our estimates on lower lending growth and margins. ~70% of value creation & 38% of new bank is fair at 1.1x BV. Lower to HOLD, unchg TP.
Q3e: its CET1 looks very attractive for EO DPS. Estimates trimmed on changed interest rate path. BUY into its IRB transition at a discount - 20% upside.
Q2: adj. PBLL -7% vs. ABGSCe on softer costs & other income. Estimates down -4% and -3% on same topic for '24e-'25e.Reiterate BUY, as excess capital will convert to dividends.
Adj. PTP beat of 8% vs. ABGSCe, 4% vs cons, driven by write-backs, muted by weaker costs & other income. Cons. EPS chg. likely up for '23e, down 1-2% '24e-'25e
Adj. PTP beat of 10% vs. ABGSCe, 5% vs cons, driven by lower loan losses, muted by weaker costs. Cons. EPS chg. likely +1-2% for '23e, limited for '24e-'25e
Q1e: expect solid reports, but with a neutral risk/reward. Adj. EPS up (higher interest rates) — expect further cons. uplift. Trading in line with historical average — but record earnings